|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Urinary Incontinence | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Urinary Bladder Neck Obstruction | |||||
| 3 | More general conditions related to this trial | ||||
| Signs and Symptoms | |||||
| Urethral Diseases | |||||
| Urethral Obstruction | |||||
| Urinary Bladder Diseases | |||||
| Urination Disorders | |||||
| Urologic Diseases | |||||
| Urological Manifestations | |||||
| 4 | Interventions listed in this trial | ||||
| Tolterodine ER 4 mg QD | |||||
| Tamsulosin 0.4 mg QD | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Tamsulosin | |||||
| Tolterodine | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic alpha-Antagonists | |||||
| Adrenergic Antagonists | |||||
| Antineoplastic Agents | |||||
| Cholinergic Agents | |||||
| Cholinergic Antagonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Muscarinic Antagonists | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Pfizer | |||||